Hi, we’re HDAX

Dr. Nawar received her PhD in Medicinal Chemistry at the University of Toronto. Her expertise in drug discovery, leadership, governance and science policy, fuels HDAX’s growth through her forward-thinking vision. Recognized as the ‘2022 Rising Star’ by the Ontario Institute for Cancer Research for her leadership and innovation, Nabanita boasts an impressive portfolio including 10 high impact publications, 2 patent applications, and over 20 awards including Top Scholar at the University of Toronto, The Society of Chemical Industry Merit Award and the Canadian Silver Medal from the Chemical Institute of Canada. HDAX Tx has won over 10 recognitions and awards under her leadership, notably Effervescence Pan-Canadian Start-up Competition 2022, Medicine by Design 2021 and Sweet Pharma Day 2021.

Dr. Manaswiyoungkul brings a wealth of expertise from her background in biophysical chemistry, biochemistry and business. With degrees from the University of Waterloo and University of Toronto, she has published 14 articles, contributed to 2 patents, and received numerous academic awards. Her strategic vision at HDAX is informed by her experiences in project management, strategy consulting, business development, and training from The Wharton School, CFA Institute, and top consulting firms. Pimyupa seamlessly blends scientific knowledge and business acumen to drive operational success.

Nick Terrett is a medicinal chemist who was educated at the University of Cambridge, and has worked in drug discovery for over 40 years in both large pharmaceutical (GSK, Pfizer, Merck) and small biotech companies (Ensemble Therapeutics) in the US, UK, and Switzerland. He has advanced several candidates into the clinic and was chemistry leader and inventor for sildenafil (marketed as ViagraTM and RevatioTM). Nick has promoted new drug discovery technologies establishing Pfizer’s first combinatorial chemistry platform and while at Ensemble Tx developed DNA-encoded chemistry libraries and explored macrocycles as valuable ‘beyond Rule of 5’ drug modalities.

Dr Fleck currently serves as CEO of Janpix, Inc., an oncology-focused discovery and development company, and is the Chairman of Omniose, a bacterial vaccine discovery company. Previously, he was a Venture Advisor/Partner with Medicxi Ventures following his role as a Principal where among others he invested in and represented Medicxi Ventures on the boards of GlycoVaxyn (sold to GSK), Versartis (NASDQ: VSAS), and Novocure (NASDQ: NVCR). Earlier he was also involved in Funxional Therapeutics (sold to Boehringer Ingelheim) and Micromet (sold to Amgen). Prior to his venture career he worked at Boehringer Ingelheim where he led drug development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage. Roman received a PhD from MIT as well as an MBA from NYU Stern.

Dr Muni brings over 20 years of industry experience as an operator, investor, board member and advisor to multiple biotechnology and pharmaceutical companies. Neal currently serves as the Managing Director of RTK Group – a biopharmaceutical advisory and investment practice supporting clinical stage companies from development to commercialization – as well as Chief Operating Officer of Comera Life Sciences (NASDAQ: CMRA) and Chief Medical Officer of Unravel Biosciences, and was previously the CEO of Azurity Pharmaceuticals. Neal maintains staff appointments as Instructor in Medicine and Associate Physician at Harvard Medical School and Brigham and Women’s Hospital and is a Visiting Scholar at The Wyss Institute of Harvard University.